Search
degludec/liraglutide (Xultophy)
Indications:
- adults with type 2 diabetes inadequately controlled on basal insulin (< 50 units/day) or liraglutide (<= 1.8 mg/day)
- may afford better glycemic control than glargine [1]
Dosage:
- prefilled pen device containing a fixed dose of degludec & liraglutide
- each unit of Xultophy 100/3.6 contains:
- 1 unit of degludec & 0.036 mg of liraglutide
- QD dosing
- starting dose is 16 units (16-units degludec & 0.58 mg liraglutide
- maximum dose of 50 units corresponds to 50 units of degludec & 1.8 mg of liraglutide
Adverse effects:
- nausea
Clinical trials:
DUAL V Randomized Clinical Trial [1]
- study characteristics
- 560 adults type 2 diabetes
- hemoglobin A1c of 7-10% while taking glargine & metformin
- patients randomized to either continue glargine or switch to once-daily injections of degludec/liraglutide
- results
- at 26 weeks, mean HbA1c diminished by 1.8% with degludec/liraglutide vs 1.1% with glargine
- degludec/liraglutide recipients lost an average of 1.4 kg; glargin ecipients gained 1.8 kg
- degludec/liraglutide recipients had fewer episodes of hypoglycemic
Interactions
drug adverse effects of hypoglycemic agents
General
hypoglycemic combination
References
- Lingvay I et al
Effect of Insulin Glargine Up-titration vs Insulin Degludec/
Liraglutide on Glycated Hemoglobin Levels in Patients With
Uncontrolled Type 2 Diabetes.
The DUAL V Randomized Clinical Trial.
JAMA. 2016;315(9):898-907
PMID: 26934259
http://jama.jamanetwork.com/article.aspx?articleid=2497908
- Nainggolan L
IDegLira, LixiLan Go Head-to-head as FDA Okays Both for
Diabetes.
Medscape. Nov 22, 2016.
http://www.medscape.com/viewarticle/872224
Components
insulin degludec (Tresiba)
liraglutide (Victoza, Saxenda)